SOPHiA GENETICS SA (SOPH) Fair Value 2026

SOPH · Health Information Services ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.9 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (32/100)

Quick Summary — As of 2026-08-28, SOPHiA GENETICS SA (SOPH) trades at $8.14. QOC: 5.9/10. Value Trap Risk: 32/100 (LOW). 0/13 models active.

Key Facts

Ticker
SOPH
Price
$8.14
Quality Score
5.9/10
Value Trap Risk
32/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give SOPH?

0 Intrinsic Value Models vs. Current Price ($8.14)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is SOPHiA GENETICS SA (SOPH) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, SOPHiA GENETICS SA currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About SOPH?

0 of 13 models are currently active for SOPH. See which stocks rank higher →

How Does SOPH Rank in Health Information Services?

Among 55 Health Information Services stocks, SOPH ranks #35 by Quality of Company score. CirclFi's QOC score of 5.9/10 evaluates 32 fundamental signals. A score of 5.9 reflects mixed fundamentals.

See all Most Undervalued Health Information Services Stocks →

SOPHiA GENETICS SA operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is SOPH a Value Trap?

CirclFi's Value Trap algorithm assigns SOPH a score of 32/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for SOPHiA GENETICS SA. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, SOPHiA GENETICS SA earns a quality score of 5.9/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SOPH valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy SOPHiA GENETICS SA Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Health Information Services Stocks Should You Also Analyze?

11 related Health Information Services stocks with 13-model coverage

PBSVPharma-Bio Serv, Inc.QOC 5.9OMDAOmada Health, Inc.QOC 5.8DRIODarioHealth Corp.QOC 6.0EVHEvolent Health, Inc.QOC 5.8HTFLHeartflow, Inc.QOC 6.1AMWLAmerican Well CorporationQOC 5.8MSPRMSP Recovery, Inc.QOC 4.7PHRPhreesia, Inc.QOC 8.4NRCNRC HealthQOC 7.0DOCSDoximity, Inc.QOC 9.6HQYHealthEquity, Inc.QOC 9.5

Read investment analysis: PBSV · OMDA · DRIO · EVH · HTFL · AMWL · MSPR · PHR · NRC · DOCS · HQY

Which Other Stocks Have a Similar Quality Score to SOPH?

7 companies across all industries closest to SOPH’s Quality of Company score of 5.9/10.

JCTCJewett-Cameron Trading Company Ltd.QOC 5.9RENTRent the Runway, Inc.QOC 5.9NEGGNewegg Commerce, Inc.QOC 5.9ANGXAngel Studios, Inc.QOC 5.9QXOQXO, Inc.QOC 5.9IPWiPower Inc.QOC 5.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: JCTC · RENT · NEGG · ANGX · QXO · IPW · NVDA

Where Does SOPH Sit in CirclFi's Health Information Services Rankings?

SOPH is ranked against every other Health Information Services stock CirclFi covers in each of these screens.

See all Health Information Services stocks ranked →

What Else Do Investors Ask About SOPHiA GENETICS SA’s Valuation?

What is SOPHiA GENETICS SA's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for SOPHiA GENETICS SA (SOPH). The Quality of Company score is 5.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SOPH overvalued or undervalued right now?

At $8.14, 0 of 0 active models suggest SOPH may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits SOPHiA GENETICS SA's business model in Health Information Services.

What does a Quality of Company score of 5.9 mean for SOPH?

SOPHiA GENETICS SA's QOC of 5.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on SOPH?

CirclFi analyzes SOPH with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is SOPH a value trap in 2026?

SOPHiA GENETICS SA's Value Trap score is 32/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns SOPHiA GENETICS SA (SOPH) a Quality of Company score of 5.9/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/SOPH/ · Methodology
Primary sources for this SOPH valuation
  • Financial statements: SOPHiA GENETICS SA 10-K and 10-Q filings on SEC EDGAR (CIK 0001840706) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SOPH as of ; valuations recomputed .